Tung-Ping Su
MD, Chair of the Department of Psychiatry at Cheng Hsin General Hospital and Professor Emeritus at National Yang Ming Chiao Tung University
Data updated
Research Footprint
Tung-Ping Su appears in 6 tracked papers (2009–2023), most studied alongside Ketamine, Placebo and DMT, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Suicidality.
Most-cited paper: Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression (205 citations).
Frequent co-authors: Mu-Hong Chen, Cheng-Ta Li and Wei-Chen Lin.
Background & Research
Tung-Ping Su is a psychiatrist and clinical researcher in Taiwan with training in both Taiwan and the United States, including fellowship training at the NIMH. He has served as chair of psychiatry at Cheng Hsin General Hospital and professor emeritus at National Yang Ming Chiao Tung University, and his work has focused on treatment-resistant mood disorders, brain imaging, rTMS, and ketamine. He has published extensively and is recognized for introducing ketamine clinical trials in Asian depressed populations.
Key Impact
He is a leading Taiwanese psychiatric researcher known for pioneering clinical trials of ketamine in treatment-resistant depression and related brain-imaging studies.
Collaboration Network
18 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Tung-Ping Su is associated with.
Cheng Hsin General Hospital
A major hospital in Taipei, Taiwan, providing multidisciplinary clinical care and participating in clinical research programs.
View stakeholder →National Institute of Mental Health (NIMH)
governmentU.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
View stakeholder →